We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Bayer Aktiengesellschaft (PK) | USOTC:BAYRY | OTCMarkets | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.13 | -1.75% | 7.30 | 7.29 | 7.37 | 7.425 | 7.26 | 7.38 | 6,172,284 | 21:03:38 |
By Patrick Costello
Bayer AG (BAYN.XE) continues to pursue its plans to exit the animal-health business via a sale, the company said Thursday, following press reports of a potential deal with Elanco Animal Health Inc. (ELAN).
"Bayer is on track with its plans to exit the animal-health business," a spokesman for Bayer said. "Following a strategic review of exit options, the primary focus is on a sale."
However, the German chemical and pharmaceutical giant is considering "all value-maximizing options," he added.
Bloomberg reported Wednesday that Elanco was aiming to reach a deal to merge its business with Bayer's animal-health unit as early as next week when Elanco releases earnings Aug. 13.
Bayer declined to comment further on the reports.
The deal as currently discussed would see Bayer gain a significant minority stake in Elanco, Bloomberg says, adding that the company would likely proceed with its original plans for a sale if an agreement with Elanco can't be reached.
Bayer is expected to sell its animal-health unit for as much as 8 billion euros ($8.97 billion) as part of its wider strategy of paring down its business following its acquisition of Monsanto Co., according to Bloomberg.
Write to Patrick Costello at patrick.costello@dowjones.com.
(END) Dow Jones Newswires
August 08, 2019 03:22 ET (07:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Bayer Aktiengesellschaft (PK) Chart |
1 Month Bayer Aktiengesellschaft (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions